Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. Issue 4 (8th December 2020)

• Record Type: Journal Article
• Authors: Arafet, Kemel; Serrano-Aparicio, Natalia; Lodola, Alessio; Mulholland, Adrian J.; González, Florenci V.; Świderek, Katarzyna; Moliner, Vicent
• Is Part Of: Chemical science. Volume 12:Issue 4(2021)
• Page Start: 1433
• Page End: 1444
• Publication Date: 2020-12-08
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d0sc06195f
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : QM/MM simulations identify the mechanism of reaction of N3, a covalent peptidyl inhibitor of SARS-CoV-2 main protease. Modelling of two novel proposed compounds, B1 and B2, suggests that reversibility of covalent inhibition could be tailored. Abstract : The SARS-CoV-2 main protease (M pro ) is essential for replication of the virus responsible for the COVID-19 pandemic, and one of the main targets for drug design. Here, we simulate the inhibition process of SARS-CoV-2 M pro with a known Michael acceptor (peptidyl) inhibitor, N3 . The free energy landscape for the mechanism of the formation of the covalent enzyme-inhibitor product is computed with QM/MM molecular dynamics methods. The simulations show a two-step mechanism, and give structures and calculated barriers in good agreement with experiment. Using these results and information from our previous investigation on the proteolysis reaction of SARS-CoV-2 M pro, we design two new, synthetically accessible N3 -analogues as potential inhibitors, in which the recognition and warhead motifs are modified. QM/MM modelling of the mechanism of inhibition of M pro by these novel compounds indicates that both may be promising candidates as drug leads against COVID-19, one as an irreversible inhibitor and one as a potential reversible inhibitor.